

September 22, 2008

ONO PHARMACEUTICAL CO., LTD.

President and Representative Director: Gyo Sagara

Code No: 4528 at the first section of the Tokyo and Osaka Stock Exchange

INQUIRIES: Kinya Morimoto, Managing Director, Public Relations (Phone: 06 6263 5670)

Announcement on Completion of Acquisition of the Company's Own Shares

(pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Corporate Law of Japan)

Ono Pharmaceutical Co., Ltd. announced today that it completed an acquisition of its own shares pursuant to Article 156 of the Corporate Law of Japan which is applicable in accordance with Article 165, paragraph 3 of the same as follows. The acquisition had been resolved at the meeting of its Board of Directors held on April 14, 2008.

(1)	Class of shares acquired	Common stock of the company
(2)	Total number of shares acquired	598,800 shares
(3)	Aggregate amount of acquisition cost	JPY 3,191,645,000
(4)	Period of acquisition	From September 1, 2008 To September 26, 2008 (delivery and receipt basis)
(5)	Method of acquisition	Purchased on the Osaka Stock Exchange

(Reference)

1. Resolution at the meeting of its Board of Directors held on April 14, 2008.

(1)	Class of shares to be acquired	Common stock of the company
(2)	Total number of shares to be acquired	5,500,000 shares (maximum) (equivalent to 4.55% of a total number of the company's shares issued)
(3)	Aggregate amount of acquisition cost	JPY 30 billion (maximum)
(4)	Period of acquisition	From April 15, 2008 To September 30, 2008

2. Accumulated company's own shares acquired based on the above resolution

(as of September 22, 2008)

(1)	Total number of shares acquired	4,626,800 shares
(2)	Aggregate amount of acquisition cost	JPY 26,519,459,000